"Discordant" increases in CD4 cell count relative to plasma viral load in a closely followed cohort of patients initiating antiretroviral therapy

Journal of Acquired Immune Deficiency Syndromes

Volumn 30, Issue 2, 2002, Pages 159-166

  Wood, Evan ^a   Hogg, Robert S ^a   Yip, Benita ^a   Tyndall, Mark W ^a   Sherlock, Christopher H ^a   Harrigan, Richard P ^a   O'Shaughnessy, Michael V ^a   Montaner, Julio S G ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

CD4 cell count; Discordant; Paradoxical; Plasma viral load

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ARTICLE; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME; VIRUS INFECTION; VIRUS LOAD;

EID: 0036603295     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-200206010-00004     Document Type: Article

References (32)

1. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less
2. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: The INCAS Trial. Italy, The Netherlands, Canada and Australia Study
3. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
4. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy
5. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine
6. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy
7. Virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV-infected patients
8. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: A prospective cohort study. Swiss HIV Cohort Study
9. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma
10. Use of changes in plasma levels of human immunodeficiency virus type 1 RNA to assess the clinical benefit of antiretroviral therapy
11. CD4 cell count in HIV-1-infected individuals remaining viraemic with highly active antiretroviral therapy (HAART). Swiss HIV Cohort Study
12. Improvement in CD4+ cell counts despite persistently detectable HIV load
13. + T cell response after virologic failure of protease inhibitor-based regimens in patients with human immunodeficiency virus infection
14. Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy
15. Decreased HIV-associated T cell apoptosis by HIV protease inhibitors
16. Viral fitness in patients with discordant CD4 and plasma HIV RNA evolution following protease inhibitor failure
17. Discrepant responses to triple combination antiretroviral therapy in advanced HIV disease
18. Highly active antiretroviral therapy including protease inhibitors does not confer a unique CD4 cell benefit
19. Full suppression of viral load is needed to achieve an optimal CD4 cell count response among patients on triple drug antiretroviral therapy
20. Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel
21. Antiretroviral therapy in adults: Updated recommendations of the International AIDS Society-USA Panel
22. Adherence to triple therapy and viral load response
23. Factors associated with the response to antiretroviral therapy among HIV-infected patients with and without a history of injection drug use
24. Determinants of paradoxical CD4 cell reconstitution after protease inhibitor-containing antiretroviral regimen
25. HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load
26. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy
27. Factors associated with the successful modification of antiretroviral therapy
28. Multiple drug rescue therapy for HIV-infected individuals with prior virologic failure to multiple regimens
29. 3. A double-blind, randomized, controlled trial
30. Do dual nucleoside regimens have a role in an era of plasma viral load-driven antiretroviral therapy?
31. Impaired fitness of human immunodeficiency virus type 1 variants with high-level resistance to protease inhibitors
32. + T cells in human immunodeficiency virus-infected patients experiencing virologic treatment failure: Role of changes in thymic output and T cell death